首页>Prostate cancer and prostatic diseases>Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study
Pharmacotherapy vs. minimally invasive therapies as initial therapy for moderate-to-severe benign prostatic hyperplasia: a cost-effectiveness study
作者单位:Toronto Health Economics and Technology Assessment Collaborative,University Health Network[1]University of Montreal Hospital Center[2]Weill Cornell Medicine[3]Division of Urology Krembil Research Institute,University Health Network[4]